nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—CYP3A4—Temozolomide—melanoma	0.263	0.576	CbGbCtD
Salbutamol—CYP3A4—Vemurafenib—melanoma	0.144	0.316	CbGbCtD
Salbutamol—CYP3A4—Docetaxel—melanoma	0.0494	0.108	CbGbCtD
Salbutamol—Isoprenaline—MAPK1—melanoma	0.00545	0.49	CrCbGaD
Salbutamol—Clenbuterol—TNF—melanoma	0.00309	0.277	CrCbGaD
Salbutamol—Flushing—Bleomycin—melanoma	0.00164	0.00348	CcSEcCtD
Salbutamol—Body temperature increased—Vemurafenib—melanoma	0.00164	0.00347	CcSEcCtD
Salbutamol—Pharyngitis—Dactinomycin—melanoma	0.00163	0.00347	CcSEcCtD
Salbutamol—Neuropathy peripheral—Temozolomide—melanoma	0.00163	0.00345	CcSEcCtD
Salbutamol—Stomatitis—Temozolomide—melanoma	0.00162	0.00343	CcSEcCtD
Salbutamol—Urinary tract infection—Temozolomide—melanoma	0.00161	0.00342	CcSEcCtD
Salbutamol—Chills—Bleomycin—melanoma	0.00158	0.00336	CcSEcCtD
Salbutamol—Sinusitis—Temozolomide—melanoma	0.00156	0.0033	CcSEcCtD
Salbutamol—Haemoglobin—Carmustine—melanoma	0.00155	0.00329	CcSEcCtD
Salbutamol—Haemorrhage—Carmustine—melanoma	0.00154	0.00327	CcSEcCtD
Salbutamol—Hypoaesthesia—Carmustine—melanoma	0.00153	0.00325	CcSEcCtD
Salbutamol—Flushing—Dactinomycin—melanoma	0.00153	0.00324	CcSEcCtD
Salbutamol—Hypersensitivity—Vemurafenib—melanoma	0.00153	0.00324	CcSEcCtD
Salbutamol—Connective tissue disorder—Carmustine—melanoma	0.00151	0.00321	CcSEcCtD
Salbutamol—Atrial fibrillation—Docetaxel—melanoma	0.00151	0.00321	CcSEcCtD
Salbutamol—Haemoglobin—Temozolomide—melanoma	0.0015	0.00318	CcSEcCtD
Salbutamol—Haemorrhage—Temozolomide—melanoma	0.00149	0.00316	CcSEcCtD
Salbutamol—Asthenia—Vemurafenib—melanoma	0.00149	0.00315	CcSEcCtD
Salbutamol—Hypoaesthesia—Temozolomide—melanoma	0.00148	0.00315	CcSEcCtD
Salbutamol—Pharyngitis—Temozolomide—melanoma	0.00148	0.00314	CcSEcCtD
Salbutamol—Chills—Dactinomycin—melanoma	0.00148	0.00314	CcSEcCtD
Salbutamol—Urinary tract disorder—Temozolomide—melanoma	0.00147	0.00312	CcSEcCtD
Salbutamol—Pruritus—Vemurafenib—melanoma	0.00147	0.00311	CcSEcCtD
Salbutamol—Connective tissue disorder—Temozolomide—melanoma	0.00146	0.00311	CcSEcCtD
Salbutamol—Urethral disorder—Temozolomide—melanoma	0.00146	0.0031	CcSEcCtD
Salbutamol—Flushing—Carmustine—melanoma	0.00143	0.00304	CcSEcCtD
Salbutamol—Ill-defined disorder—Bleomycin—melanoma	0.00143	0.00303	CcSEcCtD
Salbutamol—Diarrhoea—Vemurafenib—melanoma	0.00142	0.00301	CcSEcCtD
Salbutamol—Migraine—Docetaxel—melanoma	0.00141	0.00299	CcSEcCtD
Salbutamol—Tinnitus—Temozolomide—melanoma	0.00139	0.00295	CcSEcCtD
Salbutamol—Malaise—Bleomycin—melanoma	0.00139	0.00294	CcSEcCtD
Salbutamol—Flushing—Temozolomide—melanoma	0.00138	0.00293	CcSEcCtD
Salbutamol—Cardiac disorder—Temozolomide—melanoma	0.00138	0.00293	CcSEcCtD
Salbutamol—Arrhythmia—Carmustine—melanoma	0.00138	0.00292	CcSEcCtD
Salbutamol—Dizziness—Vemurafenib—melanoma	0.00137	0.00291	CcSEcCtD
Salbutamol—Angiopathy—Temozolomide—melanoma	0.00135	0.00287	CcSEcCtD
Salbutamol—Mental disorder—Carmustine—melanoma	0.00135	0.00287	CcSEcCtD
Salbutamol—Ataxia—Docetaxel—melanoma	0.00135	0.00286	CcSEcCtD
Salbutamol—Immune system disorder—Temozolomide—melanoma	0.00135	0.00286	CcSEcCtD
Salbutamol—Mediastinal disorder—Temozolomide—melanoma	0.00134	0.00285	CcSEcCtD
Salbutamol—Malnutrition—Carmustine—melanoma	0.00134	0.00285	CcSEcCtD
Salbutamol—Cough—Bleomycin—melanoma	0.00134	0.00285	CcSEcCtD
Salbutamol—Chills—Temozolomide—melanoma	0.00134	0.00284	CcSEcCtD
Salbutamol—Ill-defined disorder—Dactinomycin—melanoma	0.00133	0.00282	CcSEcCtD
Salbutamol—Vomiting—Vemurafenib—melanoma	0.00132	0.00279	CcSEcCtD
Salbutamol—Chest pain—Bleomycin—melanoma	0.00131	0.00278	CcSEcCtD
Salbutamol—Myalgia—Bleomycin—melanoma	0.00131	0.00278	CcSEcCtD
Salbutamol—Abdominal pain upper—Docetaxel—melanoma	0.00131	0.00278	CcSEcCtD
Salbutamol—Rash—Vemurafenib—melanoma	0.00131	0.00277	CcSEcCtD
Salbutamol—Mental disorder—Temozolomide—melanoma	0.0013	0.00277	CcSEcCtD
Salbutamol—Dermatitis—Vemurafenib—melanoma	0.0013	0.00277	CcSEcCtD
Salbutamol—Back pain—Carmustine—melanoma	0.0013	0.00275	CcSEcCtD
Salbutamol—Headache—Vemurafenib—melanoma	0.0013	0.00275	CcSEcCtD
Salbutamol—Malnutrition—Temozolomide—melanoma	0.0013	0.00275	CcSEcCtD
Salbutamol—Epinephrine—TNF—melanoma	0.0013	0.116	CrCbGaD
Salbutamol—Discomfort—Bleomycin—melanoma	0.00129	0.00274	CcSEcCtD
Salbutamol—Malaise—Dactinomycin—melanoma	0.00129	0.00274	CcSEcCtD
Salbutamol—Nadolol—ABCB1—melanoma	0.00129	0.116	CrCbGaD
Salbutamol—Cramp muscle—Docetaxel—melanoma	0.00129	0.00274	CcSEcCtD
Salbutamol—Nasopharyngitis—Docetaxel—melanoma	0.00128	0.00272	CcSEcCtD
Salbutamol—Dysgeusia—Temozolomide—melanoma	0.00127	0.00269	CcSEcCtD
Salbutamol—Tremor—Carmustine—melanoma	0.00126	0.00267	CcSEcCtD
Salbutamol—Oedema—Bleomycin—melanoma	0.00125	0.00266	CcSEcCtD
Salbutamol—Anaphylactic shock—Bleomycin—melanoma	0.00125	0.00266	CcSEcCtD
Salbutamol—Back pain—Temozolomide—melanoma	0.00125	0.00266	CcSEcCtD
Salbutamol—Infection—Bleomycin—melanoma	0.00125	0.00265	CcSEcCtD
Salbutamol—Agitation—Carmustine—melanoma	0.00123	0.00262	CcSEcCtD
Salbutamol—Nausea—Vemurafenib—melanoma	0.00123	0.00261	CcSEcCtD
Salbutamol—Myalgia—Dactinomycin—melanoma	0.00122	0.00259	CcSEcCtD
Salbutamol—Bronchospasm—Docetaxel—melanoma	0.00122	0.00258	CcSEcCtD
Salbutamol—Tremor—Temozolomide—melanoma	0.00121	0.00258	CcSEcCtD
Salbutamol—Discomfort—Dactinomycin—melanoma	0.00121	0.00256	CcSEcCtD
Salbutamol—Angina pectoris—Docetaxel—melanoma	0.00121	0.00256	CcSEcCtD
Salbutamol—Ill-defined disorder—Temozolomide—melanoma	0.0012	0.00255	CcSEcCtD
Salbutamol—Anorexia—Bleomycin—melanoma	0.0012	0.00254	CcSEcCtD
Salbutamol—Agitation—Temozolomide—melanoma	0.00119	0.00253	CcSEcCtD
Salbutamol—Angioedema—Temozolomide—melanoma	0.00118	0.00251	CcSEcCtD
Salbutamol—Hypotension—Bleomycin—melanoma	0.00117	0.00249	CcSEcCtD
Salbutamol—Oedema—Dactinomycin—melanoma	0.00117	0.00248	CcSEcCtD
Salbutamol—Malaise—Temozolomide—melanoma	0.00117	0.00248	CcSEcCtD
Salbutamol—Vertigo—Temozolomide—melanoma	0.00116	0.00247	CcSEcCtD
Salbutamol—Infection—Dactinomycin—melanoma	0.00116	0.00247	CcSEcCtD
Salbutamol—Hypertension—Carmustine—melanoma	0.00116	0.00246	CcSEcCtD
Salbutamol—Palpitations—Temozolomide—melanoma	0.00115	0.00243	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Bleomycin—melanoma	0.00114	0.00243	CcSEcCtD
Salbutamol—Chest pain—Carmustine—melanoma	0.00114	0.00242	CcSEcCtD
Salbutamol—Myalgia—Carmustine—melanoma	0.00114	0.00242	CcSEcCtD
Salbutamol—Anxiety—Carmustine—melanoma	0.00114	0.00242	CcSEcCtD
Salbutamol—Cough—Temozolomide—melanoma	0.00113	0.0024	CcSEcCtD
Salbutamol—Paraesthesia—Bleomycin—melanoma	0.00113	0.00239	CcSEcCtD
Salbutamol—Hypertension—Temozolomide—melanoma	0.00112	0.00238	CcSEcCtD
Salbutamol—Dyspnoea—Bleomycin—melanoma	0.00112	0.00237	CcSEcCtD
Salbutamol—Anorexia—Dactinomycin—melanoma	0.00112	0.00237	CcSEcCtD
Salbutamol—Myalgia—Temozolomide—melanoma	0.0011	0.00234	CcSEcCtD
Salbutamol—Arthralgia—Temozolomide—melanoma	0.0011	0.00234	CcSEcCtD
Salbutamol—Anxiety—Temozolomide—melanoma	0.0011	0.00233	CcSEcCtD
Salbutamol—Oedema—Carmustine—melanoma	0.0011	0.00232	CcSEcCtD
Salbutamol—Discomfort—Temozolomide—melanoma	0.00109	0.00231	CcSEcCtD
Salbutamol—Decreased appetite—Bleomycin—melanoma	0.00109	0.00231	CcSEcCtD
Salbutamol—Infection—Carmustine—melanoma	0.00109	0.00231	CcSEcCtD
Salbutamol—Neuropathy peripheral—Docetaxel—melanoma	0.00108	0.0023	CcSEcCtD
Salbutamol—Dry mouth—Temozolomide—melanoma	0.00108	0.00229	CcSEcCtD
Salbutamol—Stomatitis—Docetaxel—melanoma	0.00108	0.00228	CcSEcCtD
Salbutamol—Jaundice—Docetaxel—melanoma	0.00108	0.00228	CcSEcCtD
Salbutamol—Pain—Bleomycin—melanoma	0.00107	0.00228	CcSEcCtD
Salbutamol—Conjunctivitis—Docetaxel—melanoma	0.00107	0.00228	CcSEcCtD
Salbutamol—Tachycardia—Carmustine—melanoma	0.00107	0.00227	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00107	0.00226	CcSEcCtD
Salbutamol—Oedema—Temozolomide—melanoma	0.00106	0.00225	CcSEcCtD
Salbutamol—Anaphylactic shock—Temozolomide—melanoma	0.00106	0.00225	CcSEcCtD
Salbutamol—Infection—Temozolomide—melanoma	0.00105	0.00223	CcSEcCtD
Salbutamol—Anorexia—Carmustine—melanoma	0.00104	0.00222	CcSEcCtD
Salbutamol—Epistaxis—Docetaxel—melanoma	0.00104	0.00221	CcSEcCtD
Salbutamol—Nervous system disorder—Temozolomide—melanoma	0.00104	0.0022	CcSEcCtD
Salbutamol—Feeling abnormal—Bleomycin—melanoma	0.00103	0.00219	CcSEcCtD
Salbutamol—Skin disorder—Temozolomide—melanoma	0.00103	0.00218	CcSEcCtD
Salbutamol—Hypotension—Carmustine—melanoma	0.00102	0.00217	CcSEcCtD
Salbutamol—Hyperhidrosis—Temozolomide—melanoma	0.00102	0.00217	CcSEcCtD
Salbutamol—Decreased appetite—Dactinomycin—melanoma	0.00102	0.00216	CcSEcCtD
Salbutamol—Fatigue—Dactinomycin—melanoma	0.00101	0.00214	CcSEcCtD
Salbutamol—Anorexia—Temozolomide—melanoma	0.00101	0.00214	CcSEcCtD
Salbutamol—Pain—Dactinomycin—melanoma	0.001	0.00212	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Carmustine—melanoma	0.000998	0.00212	CcSEcCtD
Salbutamol—Urticaria—Bleomycin—melanoma	0.000997	0.00212	CcSEcCtD
Salbutamol—Haemoglobin—Docetaxel—melanoma	0.000996	0.00211	CcSEcCtD
Salbutamol—Rhinitis—Docetaxel—melanoma	0.000993	0.00211	CcSEcCtD
Salbutamol—Body temperature increased—Bleomycin—melanoma	0.000992	0.0021	CcSEcCtD
Salbutamol—Haemorrhage—Docetaxel—melanoma	0.000991	0.0021	CcSEcCtD
Salbutamol—Insomnia—Carmustine—melanoma	0.00099	0.0021	CcSEcCtD
Salbutamol—Hypoaesthesia—Docetaxel—melanoma	0.000986	0.00209	CcSEcCtD
Salbutamol—Paraesthesia—Carmustine—melanoma	0.000983	0.00209	CcSEcCtD
Salbutamol—Pharyngitis—Docetaxel—melanoma	0.000983	0.00209	CcSEcCtD
Salbutamol—Urinary tract disorder—Docetaxel—melanoma	0.000978	0.00208	CcSEcCtD
Salbutamol—Dyspnoea—Carmustine—melanoma	0.000976	0.00207	CcSEcCtD
Salbutamol—Somnolence—Carmustine—melanoma	0.000974	0.00207	CcSEcCtD
Salbutamol—Connective tissue disorder—Docetaxel—melanoma	0.000973	0.00207	CcSEcCtD
Salbutamol—Urethral disorder—Docetaxel—melanoma	0.000971	0.00206	CcSEcCtD
Salbutamol—Feeling abnormal—Dactinomycin—melanoma	0.000964	0.00205	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Temozolomide—melanoma	0.000964	0.00205	CcSEcCtD
Salbutamol—Insomnia—Temozolomide—melanoma	0.000957	0.00203	CcSEcCtD
Salbutamol—Gastrointestinal pain—Dactinomycin—melanoma	0.000957	0.00203	CcSEcCtD
Salbutamol—Decreased appetite—Carmustine—melanoma	0.000952	0.00202	CcSEcCtD
Salbutamol—Paraesthesia—Temozolomide—melanoma	0.00095	0.00202	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Carmustine—melanoma	0.000945	0.00201	CcSEcCtD
Salbutamol—Dyspnoea—Temozolomide—melanoma	0.000943	0.002	CcSEcCtD
Salbutamol—Somnolence—Temozolomide—melanoma	0.000941	0.002	CcSEcCtD
Salbutamol—Pain—Carmustine—melanoma	0.000936	0.00199	CcSEcCtD
Salbutamol—Constipation—Carmustine—melanoma	0.000936	0.00199	CcSEcCtD
Salbutamol—Dyspepsia—Temozolomide—melanoma	0.000932	0.00198	CcSEcCtD
Salbutamol—Abdominal pain—Dactinomycin—melanoma	0.000925	0.00196	CcSEcCtD
Salbutamol—Body temperature increased—Dactinomycin—melanoma	0.000925	0.00196	CcSEcCtD
Salbutamol—Hypersensitivity—Bleomycin—melanoma	0.000924	0.00196	CcSEcCtD
Salbutamol—Decreased appetite—Temozolomide—melanoma	0.00092	0.00195	CcSEcCtD
Salbutamol—Cardiac disorder—Docetaxel—melanoma	0.000919	0.00195	CcSEcCtD
Salbutamol—Flushing—Docetaxel—melanoma	0.000919	0.00195	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Temozolomide—melanoma	0.000914	0.00194	CcSEcCtD
Salbutamol—Fatigue—Temozolomide—melanoma	0.000912	0.00194	CcSEcCtD
Salbutamol—Pain—Temozolomide—melanoma	0.000905	0.00192	CcSEcCtD
Salbutamol—Constipation—Temozolomide—melanoma	0.000905	0.00192	CcSEcCtD
Salbutamol—Feeling abnormal—Carmustine—melanoma	0.000902	0.00192	CcSEcCtD
Salbutamol—Asthenia—Bleomycin—melanoma	0.0009	0.00191	CcSEcCtD
Salbutamol—Angiopathy—Docetaxel—melanoma	0.000899	0.00191	CcSEcCtD
Salbutamol—Gastrointestinal pain—Carmustine—melanoma	0.000895	0.0019	CcSEcCtD
Salbutamol—Immune system disorder—Docetaxel—melanoma	0.000895	0.0019	CcSEcCtD
Salbutamol—Mediastinal disorder—Docetaxel—melanoma	0.000893	0.00189	CcSEcCtD
Salbutamol—Chills—Docetaxel—melanoma	0.000889	0.00189	CcSEcCtD
Salbutamol—Pruritus—Bleomycin—melanoma	0.000888	0.00188	CcSEcCtD
Salbutamol—Arrhythmia—Docetaxel—melanoma	0.000885	0.00188	CcSEcCtD
Salbutamol—Feeling abnormal—Temozolomide—melanoma	0.000872	0.00185	CcSEcCtD
Salbutamol—Mental disorder—Docetaxel—melanoma	0.000868	0.00184	CcSEcCtD
Salbutamol—Body temperature increased—Carmustine—melanoma	0.000866	0.00184	CcSEcCtD
Salbutamol—Abdominal pain—Carmustine—melanoma	0.000866	0.00184	CcSEcCtD
Salbutamol—Gastrointestinal pain—Temozolomide—melanoma	0.000865	0.00184	CcSEcCtD
Salbutamol—Malnutrition—Docetaxel—melanoma	0.000862	0.00183	CcSEcCtD
Salbutamol—Hypersensitivity—Dactinomycin—melanoma	0.000862	0.00183	CcSEcCtD
Salbutamol—Dysgeusia—Docetaxel—melanoma	0.000844	0.00179	CcSEcCtD
Salbutamol—Urticaria—Temozolomide—melanoma	0.000841	0.00178	CcSEcCtD
Salbutamol—Asthenia—Dactinomycin—melanoma	0.000839	0.00178	CcSEcCtD
Salbutamol—Abdominal pain—Temozolomide—melanoma	0.000837	0.00178	CcSEcCtD
Salbutamol—Body temperature increased—Temozolomide—melanoma	0.000837	0.00178	CcSEcCtD
Salbutamol—Back pain—Docetaxel—melanoma	0.000834	0.00177	CcSEcCtD
Salbutamol—Muscle spasms—Docetaxel—melanoma	0.000829	0.00176	CcSEcCtD
Salbutamol—Hypersensitivity—Carmustine—melanoma	0.000807	0.00171	CcSEcCtD
Salbutamol—Diarrhoea—Dactinomycin—melanoma	0.000801	0.0017	CcSEcCtD
Salbutamol—Vomiting—Bleomycin—melanoma	0.000798	0.00169	CcSEcCtD
Salbutamol—Rash—Bleomycin—melanoma	0.000791	0.00168	CcSEcCtD
Salbutamol—Dermatitis—Bleomycin—melanoma	0.00079	0.00168	CcSEcCtD
Salbutamol—Asthenia—Carmustine—melanoma	0.000786	0.00167	CcSEcCtD
Salbutamol—Hypersensitivity—Temozolomide—melanoma	0.00078	0.00165	CcSEcCtD
Salbutamol—Syncope—Docetaxel—melanoma	0.000773	0.00164	CcSEcCtD
Salbutamol—Palpitations—Docetaxel—melanoma	0.000762	0.00162	CcSEcCtD
Salbutamol—Asthenia—Temozolomide—melanoma	0.000759	0.00161	CcSEcCtD
Salbutamol—Loss of consciousness—Docetaxel—melanoma	0.000758	0.00161	CcSEcCtD
Salbutamol—Cough—Docetaxel—melanoma	0.000752	0.0016	CcSEcCtD
Salbutamol—Diarrhoea—Carmustine—melanoma	0.000749	0.00159	CcSEcCtD
Salbutamol—Pruritus—Temozolomide—melanoma	0.000749	0.00159	CcSEcCtD
Salbutamol—Nausea—Bleomycin—melanoma	0.000745	0.00158	CcSEcCtD
Salbutamol—Hypertension—Docetaxel—melanoma	0.000744	0.00158	CcSEcCtD
Salbutamol—Vomiting—Dactinomycin—melanoma	0.000744	0.00158	CcSEcCtD
Salbutamol—Rash—Dactinomycin—melanoma	0.000738	0.00157	CcSEcCtD
Salbutamol—Arthralgia—Docetaxel—melanoma	0.000734	0.00156	CcSEcCtD
Salbutamol—Chest pain—Docetaxel—melanoma	0.000734	0.00156	CcSEcCtD
Salbutamol—Myalgia—Docetaxel—melanoma	0.000734	0.00156	CcSEcCtD
Salbutamol—Dizziness—Carmustine—melanoma	0.000724	0.00154	CcSEcCtD
Salbutamol—Diarrhoea—Temozolomide—melanoma	0.000724	0.00154	CcSEcCtD
Salbutamol—Dry mouth—Docetaxel—melanoma	0.000718	0.00152	CcSEcCtD
Salbutamol—Oedema—Docetaxel—melanoma	0.000704	0.00149	CcSEcCtD
Salbutamol—Anaphylactic shock—Docetaxel—melanoma	0.000704	0.00149	CcSEcCtD
Salbutamol—Dizziness—Temozolomide—melanoma	0.0007	0.00149	CcSEcCtD
Salbutamol—Infection—Docetaxel—melanoma	0.000699	0.00148	CcSEcCtD
Salbutamol—Vomiting—Carmustine—melanoma	0.000696	0.00148	CcSEcCtD
Salbutamol—Nausea—Dactinomycin—melanoma	0.000695	0.00148	CcSEcCtD
Salbutamol—Shock—Docetaxel—melanoma	0.000692	0.00147	CcSEcCtD
Salbutamol—Rash—Carmustine—melanoma	0.00069	0.00147	CcSEcCtD
Salbutamol—Nervous system disorder—Docetaxel—melanoma	0.00069	0.00146	CcSEcCtD
Salbutamol—Dermatitis—Carmustine—melanoma	0.00069	0.00146	CcSEcCtD
Salbutamol—Tachycardia—Docetaxel—melanoma	0.000687	0.00146	CcSEcCtD
Salbutamol—Headache—Carmustine—melanoma	0.000686	0.00146	CcSEcCtD
Salbutamol—Skin disorder—Docetaxel—melanoma	0.000684	0.00145	CcSEcCtD
Salbutamol—Vomiting—Temozolomide—melanoma	0.000673	0.00143	CcSEcCtD
Salbutamol—Anorexia—Docetaxel—melanoma	0.000671	0.00142	CcSEcCtD
Salbutamol—Rash—Temozolomide—melanoma	0.000667	0.00142	CcSEcCtD
Salbutamol—Dermatitis—Temozolomide—melanoma	0.000667	0.00141	CcSEcCtD
Salbutamol—Headache—Temozolomide—melanoma	0.000663	0.00141	CcSEcCtD
Salbutamol—Hypotension—Docetaxel—melanoma	0.000658	0.0014	CcSEcCtD
Salbutamol—Nausea—Carmustine—melanoma	0.00065	0.00138	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Docetaxel—melanoma	0.000641	0.00136	CcSEcCtD
Salbutamol—Insomnia—Docetaxel—melanoma	0.000637	0.00135	CcSEcCtD
Salbutamol—Paraesthesia—Docetaxel—melanoma	0.000632	0.00134	CcSEcCtD
Salbutamol—Nausea—Temozolomide—melanoma	0.000629	0.00133	CcSEcCtD
Salbutamol—Dyspnoea—Docetaxel—melanoma	0.000627	0.00133	CcSEcCtD
Salbutamol—Somnolence—Docetaxel—melanoma	0.000626	0.00133	CcSEcCtD
Salbutamol—Dyspepsia—Docetaxel—melanoma	0.000619	0.00131	CcSEcCtD
Salbutamol—Decreased appetite—Docetaxel—melanoma	0.000612	0.0013	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Docetaxel—melanoma	0.000608	0.00129	CcSEcCtD
Salbutamol—Fatigue—Docetaxel—melanoma	0.000607	0.00129	CcSEcCtD
Salbutamol—Pain—Docetaxel—melanoma	0.000602	0.00128	CcSEcCtD
Salbutamol—Constipation—Docetaxel—melanoma	0.000602	0.00128	CcSEcCtD
Salbutamol—Feeling abnormal—Docetaxel—melanoma	0.00058	0.00123	CcSEcCtD
Salbutamol—Gastrointestinal pain—Docetaxel—melanoma	0.000575	0.00122	CcSEcCtD
Salbutamol—Abdominal pain—Docetaxel—melanoma	0.000556	0.00118	CcSEcCtD
Salbutamol—Body temperature increased—Docetaxel—melanoma	0.000556	0.00118	CcSEcCtD
Salbutamol—Hypersensitivity—Docetaxel—melanoma	0.000518	0.0011	CcSEcCtD
Salbutamol—Asthenia—Docetaxel—melanoma	0.000505	0.00107	CcSEcCtD
Salbutamol—Pruritus—Docetaxel—melanoma	0.000498	0.00106	CcSEcCtD
Salbutamol—Diarrhoea—Docetaxel—melanoma	0.000482	0.00102	CcSEcCtD
Salbutamol—Dizziness—Docetaxel—melanoma	0.000465	0.000988	CcSEcCtD
Salbutamol—Vomiting—Docetaxel—melanoma	0.000447	0.00095	CcSEcCtD
Salbutamol—Rash—Docetaxel—melanoma	0.000444	0.000942	CcSEcCtD
Salbutamol—Dermatitis—Docetaxel—melanoma	0.000443	0.000941	CcSEcCtD
Salbutamol—Headache—Docetaxel—melanoma	0.000441	0.000936	CcSEcCtD
Salbutamol—Nausea—Docetaxel—melanoma	0.000418	0.000887	CcSEcCtD
Salbutamol—ADRB1—Signaling Pathways—HDAC6—melanoma	5.12e-05	0.00083	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—EDN1—melanoma	5.07e-05	0.000822	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ACER3—melanoma	5.02e-05	0.000814	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HDAC6—melanoma	5e-05	0.000812	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—EDN1—melanoma	4.96e-05	0.000804	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CSF2—melanoma	4.95e-05	0.000804	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCR2—melanoma	4.85e-05	0.000787	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—CXCL8—melanoma	4.85e-05	0.000786	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CSF2—melanoma	4.85e-05	0.000786	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RAC2—melanoma	4.77e-05	0.000774	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PRKCA—melanoma	4.75e-05	0.00077	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCR2—melanoma	4.74e-05	0.00077	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—CXCL8—melanoma	4.74e-05	0.000769	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—WNT5A—melanoma	4.7e-05	0.000762	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VEGFC—melanoma	4.7e-05	0.000762	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RAC2—melanoma	4.67e-05	0.000757	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PRKCA—melanoma	4.65e-05	0.000754	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EDN1—melanoma	4.6e-05	0.000747	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VEGFC—melanoma	4.59e-05	0.000745	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—WNT5A—melanoma	4.59e-05	0.000745	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—UGT2B10—melanoma	4.59e-05	0.000745	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EDN1—melanoma	4.5e-05	0.00073	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CSF2—melanoma	4.5e-05	0.00073	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—RAC1—melanoma	4.4e-05	0.000714	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CSF2—melanoma	4.4e-05	0.000714	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PRKCA—melanoma	4.31e-05	0.0007	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—RAC1—melanoma	4.31e-05	0.000699	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HS3ST5—melanoma	4.27e-05	0.000692	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PRKCA—melanoma	4.22e-05	0.000684	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MAP2K2—melanoma	4.22e-05	0.000684	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MAP2K2—melanoma	4.12e-05	0.000669	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—F2R—melanoma	4.12e-05	0.000669	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—F2R—melanoma	4.03e-05	0.000654	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—RAC1—melanoma	4e-05	0.000649	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EDNRB—melanoma	3.99e-05	0.000648	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—RAC1—melanoma	3.91e-05	0.000635	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EDNRB—melanoma	3.91e-05	0.000634	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTK2B—melanoma	3.88e-05	0.000629	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTK2B—melanoma	3.79e-05	0.000615	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GNA11—melanoma	3.77e-05	0.000612	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GAB2—melanoma	3.77e-05	0.000612	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FLT1—melanoma	3.76e-05	0.000609	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CG—melanoma	3.72e-05	0.000603	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GNA11—melanoma	3.69e-05	0.000599	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GAB2—melanoma	3.69e-05	0.000599	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FLT1—melanoma	3.67e-05	0.000596	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CG—melanoma	3.64e-05	0.00059	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HDAC2—melanoma	3.55e-05	0.000575	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCR4—melanoma	3.55e-05	0.000575	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FOXO4—melanoma	3.55e-05	0.000575	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GNAQ—melanoma	3.51e-05	0.000569	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HDAC2—melanoma	3.47e-05	0.000563	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FOXO4—melanoma	3.47e-05	0.000563	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCR4—melanoma	3.47e-05	0.000563	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GNAQ—melanoma	3.43e-05	0.000556	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CG—melanoma	3.38e-05	0.000548	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CG—melanoma	3.3e-05	0.000536	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SYK—melanoma	3.3e-05	0.000535	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CD—melanoma	3.27e-05	0.000531	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ITGAV—melanoma	3.24e-05	0.000525	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKT3—melanoma	3.24e-05	0.000525	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NGFR—melanoma	3.24e-05	0.000525	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PLCB4—melanoma	3.23e-05	0.000525	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SYK—melanoma	3.23e-05	0.000523	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CD—melanoma	3.2e-05	0.000519	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NGFR—melanoma	3.17e-05	0.000514	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKT3—melanoma	3.17e-05	0.000514	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ITGAV—melanoma	3.17e-05	0.000514	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC6A11—melanoma	3.04e-05	0.000493	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIP4K2A—melanoma	3.04e-05	0.000493	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SOCS1—melanoma	3e-05	0.000486	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MAP2K1—melanoma	2.99e-05	0.000485	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—S100B—melanoma	2.99e-05	0.000485	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CD—melanoma	2.97e-05	0.000482	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MTAP—melanoma	2.96e-05	0.00048	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SOCS1—melanoma	2.93e-05	0.000476	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MAP2K1—melanoma	2.92e-05	0.000474	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—S100B—melanoma	2.92e-05	0.000474	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CD—melanoma	2.91e-05	0.000471	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ERBB4—melanoma	2.86e-05	0.000464	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CB—melanoma	2.85e-05	0.000462	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDKN2B—melanoma	2.83e-05	0.00046	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ERBB4—melanoma	2.8e-05	0.000454	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CB—melanoma	2.79e-05	0.000452	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDKN2B—melanoma	2.77e-05	0.00045	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CD86—melanoma	2.74e-05	0.000445	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CXCL8—melanoma	2.74e-05	0.000444	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EDN1—melanoma	2.72e-05	0.000441	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CD86—melanoma	2.68e-05	0.000435	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CXCL8—melanoma	2.68e-05	0.000435	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EDN1—melanoma	2.66e-05	0.000431	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGF1—melanoma	2.66e-05	0.000431	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CSF2—melanoma	2.66e-05	0.000431	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PHGDH—melanoma	2.64e-05	0.000428	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LUM—melanoma	2.64e-05	0.000428	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—IL2—melanoma	2.62e-05	0.000425	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—E2F1—melanoma	2.6e-05	0.000422	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CSF2—melanoma	2.6e-05	0.000422	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGF1—melanoma	2.6e-05	0.000422	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CB—melanoma	2.59e-05	0.00042	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HPSE—melanoma	2.59e-05	0.000419	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PDGFRA—melanoma	2.57e-05	0.000418	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—IL2—melanoma	2.56e-05	0.000415	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PRKCA—melanoma	2.55e-05	0.000413	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ITGB3—melanoma	2.55e-05	0.000413	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—E2F1—melanoma	2.54e-05	0.000413	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CUBN—melanoma	2.54e-05	0.000412	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CB—melanoma	2.53e-05	0.000411	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PDGFRA—melanoma	2.52e-05	0.000408	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SPP1—melanoma	2.5e-05	0.000405	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ITGB3—melanoma	2.49e-05	0.000404	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PRKCA—melanoma	2.49e-05	0.000404	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAP2K2—melanoma	2.49e-05	0.000404	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CXCL8—melanoma	2.49e-05	0.000404	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SDHD—melanoma	2.45e-05	0.000398	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CSPG4—melanoma	2.45e-05	0.000398	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—BSG—melanoma	2.45e-05	0.000398	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SPP1—melanoma	2.44e-05	0.000397	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAP2K2—melanoma	2.44e-05	0.000395	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CXCL8—melanoma	2.43e-05	0.000395	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL2—melanoma	2.38e-05	0.000386	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GPAM—melanoma	2.37e-05	0.000385	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TERT—melanoma	2.37e-05	0.000384	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RAC1—melanoma	2.36e-05	0.000383	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL2—melanoma	2.33e-05	0.000377	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TERT—melanoma	2.32e-05	0.000376	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RAC1—melanoma	2.31e-05	0.000375	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HIF1A—melanoma	2.27e-05	0.000367	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HIF1A—melanoma	2.22e-05	0.000359	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KDR—melanoma	2.17e-05	0.000351	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KDR—melanoma	2.12e-05	0.000344	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FN1—melanoma	2.09e-05	0.000338	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOTCH1—melanoma	2.04e-05	0.000331	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FN1—melanoma	2.04e-05	0.000331	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PLA2G6—melanoma	2.02e-05	0.000327	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CD80—melanoma	2e-05	0.000324	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOTCH1—melanoma	2e-05	0.000324	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KIT—melanoma	2e-05	0.000324	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APC—melanoma	2e-05	0.000324	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CG—melanoma	2e-05	0.000324	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—NRAS—melanoma	2e-05	0.000324	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EGF—melanoma	1.97e-05	0.00032	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CD80—melanoma	1.96e-05	0.000317	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KIT—melanoma	1.95e-05	0.000317	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CG—melanoma	1.95e-05	0.000317	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APC—melanoma	1.95e-05	0.000317	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—NRAS—melanoma	1.95e-05	0.000317	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EGF—melanoma	1.93e-05	0.000313	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MAPK3—melanoma	1.91e-05	0.00031	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—BRAF—melanoma	1.88e-05	0.000304	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MAPK3—melanoma	1.87e-05	0.000303	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—BRAF—melanoma	1.83e-05	0.000298	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IGF1—melanoma	1.83e-05	0.000296	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MAPK1—melanoma	1.82e-05	0.000295	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EGFR—melanoma	1.82e-05	0.000295	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—VCAN—melanoma	1.81e-05	0.000294	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IGF1—melanoma	1.79e-05	0.00029	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MAPK1—melanoma	1.78e-05	0.000289	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EGFR—melanoma	1.78e-05	0.000289	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAP2K1—melanoma	1.77e-05	0.000286	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CD—melanoma	1.75e-05	0.000285	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CA—melanoma	1.74e-05	0.000282	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAP2K1—melanoma	1.73e-05	0.00028	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—KRAS—melanoma	1.72e-05	0.000279	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CD—melanoma	1.72e-05	0.000278	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CA—melanoma	1.7e-05	0.000276	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—KRAS—melanoma	1.68e-05	0.000273	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGF2—melanoma	1.68e-05	0.000272	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGF2—melanoma	1.64e-05	0.000267	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CA—melanoma	1.58e-05	0.000256	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MDM2—melanoma	1.57e-05	0.000255	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ERBB2—melanoma	1.55e-05	0.000251	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CA—melanoma	1.54e-05	0.00025	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MDM2—melanoma	1.54e-05	0.000249	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP17A1—melanoma	1.53e-05	0.000248	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CB—melanoma	1.53e-05	0.000248	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ERBB2—melanoma	1.52e-05	0.000246	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CB—melanoma	1.5e-05	0.000243	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCL8—melanoma	1.47e-05	0.000238	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HRAS—melanoma	1.46e-05	0.000237	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GNA11—melanoma	1.44e-05	0.000234	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCL8—melanoma	1.44e-05	0.000233	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDKN1B—melanoma	1.44e-05	0.000233	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HRAS—melanoma	1.43e-05	0.000232	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AKT1—melanoma	1.42e-05	0.00023	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—FASN—melanoma	1.41e-05	0.000229	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CASP3—melanoma	1.41e-05	0.000228	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL2—melanoma	1.4e-05	0.000228	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDKN1B—melanoma	1.4e-05	0.000228	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6—melanoma	1.4e-05	0.000227	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC5A5—melanoma	1.39e-05	0.000226	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AKT1—melanoma	1.39e-05	0.000225	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CASP3—melanoma	1.38e-05	0.000223	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL2—melanoma	1.37e-05	0.000223	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCND1—melanoma	1.37e-05	0.000222	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6—melanoma	1.37e-05	0.000222	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CTNNB1—melanoma	1.36e-05	0.00022	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CD44—melanoma	1.34e-05	0.000218	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GNAQ—melanoma	1.34e-05	0.000218	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCND1—melanoma	1.34e-05	0.000217	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MMP9—melanoma	1.33e-05	0.000216	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CTNNB1—melanoma	1.33e-05	0.000215	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDKN1A—melanoma	1.32e-05	0.000215	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTEN—melanoma	1.32e-05	0.000214	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NFKB1—melanoma	1.32e-05	0.000213	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MMP9—melanoma	1.3e-05	0.000211	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDKN1A—melanoma	1.3e-05	0.00021	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTEN—melanoma	1.29e-05	0.00021	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AKT1—melanoma	1.29e-05	0.000209	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP1B1—melanoma	1.29e-05	0.000209	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NFKB1—melanoma	1.29e-05	0.000209	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AKT1—melanoma	1.26e-05	0.000205	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VEGFA—melanoma	1.19e-05	0.000194	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—STAT3—melanoma	1.18e-05	0.000192	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NRAS—melanoma	1.18e-05	0.000191	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VEGFA—melanoma	1.17e-05	0.000189	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—STAT3—melanoma	1.16e-05	0.000188	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NRAS—melanoma	1.15e-05	0.000187	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAPK3—melanoma	1.13e-05	0.000183	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAPK3—melanoma	1.1e-05	0.000179	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MYC—melanoma	1.1e-05	0.000178	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAPK1—melanoma	1.07e-05	0.000174	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MYC—melanoma	1.07e-05	0.000174	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EGFR—melanoma	1.07e-05	0.000174	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCB1—melanoma	1.06e-05	0.000172	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAPK1—melanoma	1.05e-05	0.00017	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EGFR—melanoma	1.05e-05	0.00017	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KRAS—melanoma	1.01e-05	0.000165	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KRAS—melanoma	9.93e-06	0.000161	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PRKCA—melanoma	9.76e-06	0.000158	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ERCC2—melanoma	9.68e-06	0.000157	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CA—melanoma	9.32e-06	0.000151	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CA—melanoma	9.12e-06	0.000148	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TP53—melanoma	9.02e-06	0.000146	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TP53—melanoma	8.82e-06	0.000143	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HRAS—melanoma	8.62e-06	0.00014	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HRAS—melanoma	8.44e-06	0.000137	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6—melanoma	8.25e-06	0.000134	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6—melanoma	8.07e-06	0.000131	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CG—melanoma	7.64e-06	0.000124	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKT1—melanoma	7.62e-06	0.000124	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKT1—melanoma	7.45e-06	0.000121	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPARG—melanoma	7.38e-06	0.00012	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CD—melanoma	6.72e-06	0.000109	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALB—melanoma	6.63e-06	0.000108	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CB—melanoma	5.86e-06	9.5e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTGS2—melanoma	5.8e-06	9.41e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTEN—melanoma	5.06e-06	8.21e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CA—melanoma	3.57e-06	5.79e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKT1—melanoma	2.92e-06	4.73e-05	CbGpPWpGaD
